Inactive Instrument

Highlights Synaptogenix, Inc. Other OTC

Equities

SNPX

US87167T1025

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	09/04	CI
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	02/11	CI
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/23/19	CI
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
North American Morning Briefing : Futures Waver -2-	20/22/20	DJ
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease	16/22/16	CI
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	06/22/06	CI
Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data	20/22/20	CI
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial	19/22/19	CI
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	13/21/13	CI
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	14/21/14	CI
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline	14/21/14	CI
Synaptogenix : Awarded US Patent for Treatment of Alzheimer's Disease	08/21/08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Synaptogenix, Inc. Other OTC

Equities

SNPX

US87167T1025

Highlights

Filters